Details for Patent: 11,779,557

Which drugs does patent 11,779,557 protect, and when does it expire?

Patent 11,779,557 protects LUMRYZ and is included in one NDA.

Summary for Patent: 11,779,557

Title:	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Abstract:	Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Inventor(s):	Jordan Dubow, Cendrine Grangeon, Hervé Guillard, Claire Mégret, Jean-François DUBUISSON
Assignee:	Flamel Ireland Ltd
Application Number:	US17/666,201
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,779,557
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form;

United States Patent 11,779,557 (Gamma-Hydroxybutyrate Once-Nightly) Claim Scope and US Patent Landscape

Executive summary

US Patent 11,779,557 claims a narcolepsy treatment method using a once-nightly, oral gamma-hydroxybutyrate (GHB) formulation that contains immediate-release and modified-release portions and delivers a systemic GHB exposure equivalent to specified gram ranges of sodium oxybate, with patient selection based on sleep-disordered breathing metrics (notably apnea/hypopnea index (AHI) thresholds) and post-dosing behavior instructions. Dependent claims add constraints tied to respiratory safety (central apnea and oxygen desaturation limits) and PSG measurement. A second independent method claim covers treatment exclusion for subjects with higher AHI.

The landscape around this patent is dominated by: (i) other GHB/narcolepsy patents on once-nightly formulations (split IR/extended components) and dosing equivalence; (ii) patents on patient selection and respiratory-risk management; and (iii) the broader sodium oxybate / GHB ecosystem where Orange Book and FDA labeling drive how method claims are enforced against prescribing and dispensing.

---

What does US Patent 11,779,557 claim and what is its practical scope?

Featured snippet answer: The patent claims a method of treating cataplexy or excessive daytime sleepiness in narcolepsy using a once-nightly, oral IR + modified-release GHB formulation with GHB dose equivalence to 3–9 g sodium oxybate (or 4.5–9 g in the other independent claim variant), where prescribing occurs after determining AHI ≤ 15, and includes once-per-night while in bed instructions with immediate lying down.

Independent claim structure (method of treatment with qualifying AHI)

Core elements in Claim 1:

1. Patient population: “human patient” with cataplexy or excessive daytime sleepiness due to narcolepsy.
2. Sleep-breathing selection criterion: determine the patient has AHI ≤ 15.
3. Prescription timing: prescribing occurs after the AHI determination.
4. Product regimen: prescribe a once-nightly formulation that, after oral administration, releases gamma-hydroxybutyrate into the bloodstream.
5. Formulation architecture: formulation includes an immediate-release portion and a modified-release portion.
6. Dose equivalence constraint: each once-nightly dosage releases GHB amount equivalent to 3 g to 9 g sodium oxybate.
7. Dosing instructions: patient takes formulation only once per night while in bed and lies down immediately after dosing.

Independent claim structure (treatment inclusion/exclusion based on AHI)

Claim 6 adds an allocation/exclusion paradigm:

• Identify a first subject with AHI ≤ 15 and a second subject with AHI > 15.
• Prescribe the formulation to the first subject using a dose equivalence equivalent to 4.5 g to 9 g sodium oxybate.
• Exclude the second subject based at least in part on the AHI determination.

Dependent claims that narrow safety and operational compliance

Key dependent limitations:

• Claim 2: respiratory stability, requiring that oral administration does not provide clinically significant worsening of respiratory function measured by AHI and pulse oximetry.
• Claim 3: fewer instances of central apnea compared to immediate-release sodium oxybate.
• Claim 4: no oxygen desaturation of ≤ 55%.
• Claim 5: further comprising measuring polysomnography (PSG) of the patient.

Claim-scoping implications for enforcement

• The patent is not merely about “using GHB in narcolepsy.” It is about a specific prescribing workflow plus a specific formulation architecture (IR + modified-release) and specific dosing equivalence tied to sodium oxybate grams.
• Enforcement leverage typically targets:
  • the prescriber’s patient-selection process (AHI determination and timing of prescribing),
  • labeling-like administration instructions (once nightly, while in bed, lie down immediately), and
  • proof of the formulation’s release profile and equivalence (IR/modified release; GHB exposure to sodium oxybate grams).
• A clinical study showing “improved respiratory outcomes” may be relevant but the independent claim does not require the outcomes; it requires selection (AHI ≤ 15) and dosing protocol. Dependent claims add post-treatment respiratory endpoints.

---

How do the AHI thresholds work as claim differentiators?

Featured snippet answer: AHI is used as a gatekeeping criterion. The patent limits treatment to patients with AHI ≤ 15 and includes an explicit exclusion for AHI > 15.

Why AHI ≤ 15 is a strong fence

From a litigation/validity standpoint, the AHI threshold is:

• a measurable clinical variable,
• a bright-line eligibility condition,
• tied to respiratory risk management for GHB-type therapies.

Claim 1 requires “determining” before prescribing; Claim 6 requires using AHI to decide who gets treated and who is excluded.

What counts as “determining” and “measuring”?

Claim 5 explicitly references polysomnography (PSG). This aligns AHI determination to sleep studies:

• If infringers rely on non-PSG estimates or secondary data, Claim 5 may be avoided, but Claim 1 and Claim 6 still require a “determining” step. The operational question becomes whether their workflow uses AHI derived from PSG.

---

What does “once-nightly formulation with immediate-release and modified-release portions” cover?

Featured snippet answer: The formulation limitation requires a split release profile that includes both immediate-release and modified-release components, enabling a once-nightly oral regimen.

Release architecture is the functional claim hook

The claims do not recite a polymer list or excipient identity. They require:

• immediate-release portion, plus
• modified-release portion,
• producing systemic GHB release after oral administration.

That tends to capture:

• split-release tablets/capsules,
• layered beads or multipart dosage forms,
• combination IR/extended matrices where both portions contribute to the once-nightly dosing profile.

“Gamma-hydroxybutyrate releases into the bloodstream” and dose equivalence

The claims tie to amount released being equivalent to sodium oxybate gram ranges. That introduces a conversion/equivalence issue:

• It is not “sodium oxybate administration.” It is GHB release equivalent to sodium oxybate doses.
• That can cover branded GHB formulations and generics if their pharmacokinetic exposure meets equivalence as claimed.

---

How broad is the dose equivalence range (3 g to 9 g and 4.5 g to 9 g)?

Featured snippet answer: The patent covers once-nightly doses that are equivalent to 3–9 g sodium oxybate in Claim 1 and 4.5–9 g sodium oxybate in Claim 6.

Practical coverage map

• Claim 1: includes the lower bound at the 3 g equivalent level up through the 9 g equivalent level.
• Claim 6: narrows the lower bound to 4.5 g equivalent.

This creates potential design-around space:

• Regimens that consistently dose below 4.5 g equivalent may fall outside Claim 6 but could still fall within Claim 1.
• Regimens above 9 g equivalent may fall outside both.

Litigation impact

Dose equivalence typically drives disputes about:

• pharmacokinetic equivalence,
• formulation release profile,
• assay and bioanalytical methods.

In method claims, the dosing instruction and prescribing pattern can also be relevant even if pharmacokinetic arguments are the center of a validity dispute.

---

What do the safety-related dependent claims add (respiratory function, central apnea, oxygen desaturation)?

Featured snippet answer: Dependent claims require absence of clinically significant respiratory worsening and set measurable respiratory limits: fewer central apnea events than immediate-release sodium oxybate, and no oxygen desaturation at or below 55%.

Claim 2: “clinically significant worsening” measured by AHI and pulse oximetry

This depends on:

• what “clinically significant” means operationally,
• which pulse oximetry metrics are used,
• how AHI changes are evaluated post-dose.

Claim 3: fewer central apnea instances vs immediate-release sodium oxybate

This is a comparative limitation:

• It introduces the comparator product class (“immediate-release sodium oxybate”).
• In litigation, this comparator can become a factual and technical pivot point.

Claim 4: no oxygen desaturation ≤55%

This is a hard numerical limit, which can be easier to test:

• It requires demonstrating a respiratory oxygen metric does not reach the threshold.
• If data from real-world prescribing shows occasional desaturation events, the question becomes whether the claim is construed as an absolute outcome requirement or a statistical expectation.

---

What does the PSG limitation do to claim coverage?

Featured snippet answer: Claim 5 adds a procedural element: measuring polysomnography (PSG).

How PSG narrows infringement theory

If a prescriber uses AHI from sources not requiring PSG measurement under their workflow, Claim 5 may be less likely to be met. However:

• Claim 1 and Claim 6 already require “determining” AHI thresholds.
• PSG is a likely pathway for determining AHI, so Claim 5 often tracks normal clinical workflow in narcolepsy with suspected comorbid sleep-disordered breathing.

---

What is the patent landscape for US GHB once-nightly narcolepsy methods near this claim set?

Featured snippet answer: The landscape is structured around three clusters: (1) formulation patents for once-nightly IR + modified-release GHB products; (2) method-of-use and patient-selection patents tied to respiratory risk (AHI thresholds, central apnea, oximetry); and (3) method claims anchored to prescribing instructions such as “in bed” and dosing behavior.

Cluster 1: Formulation and release-profile patents

Typical claim themes adjacent to this patent:

• IR + extended/modified release GHB formulations enabling once-nightly dosing.
• Dose-range equivalents tied to sodium oxybate grams.
• Pharmacokinetic and release profile constraints to match approved dosing.

These patents often overlap with the same product family and compete for enforcement space.

Cluster 2: Patient selection and respiratory safety patents

Other patents in the space frequently cover:

• identifying patients with sleep-disordered breathing,
• contraindications or precautions based on AHI or oxygenation measures,
• mitigation strategies reducing central apnea occurrence.

US Patent 11,779,557 is more specific because it uses AHI ≤ 15 as a gate and includes both inclusion and exclusion frameworks.

Cluster 3: Administration and “while in bed” dosing instructions

This claim includes a behavioral instruction:

• take once nightly while in bed,
• lie down immediately.

That operational detail often matters in method-of-use enforcement where label-like instructions influence infringement allegations.

---

Which earlier patents and later filings are most likely to be relevant?

Featured snippet answer: The most likely relevant US patents are those covering:

• once-nightly GHB with IR + modified-release split dosing,
• dosing equivalence to sodium oxybate gram ranges,
• and patient selection or respiratory endpoints tied to AHI, pulse oximetry, central apnea, or desaturation metrics.

How this patent’s claim language maps to patentability and design-around

• Novelty pressure would focus on whether earlier filings disclosed:
  • AHI-based selection threshold (specifically ≤15) and its timing relative to prescribing, and
  • combining that criterion with IR + modified-release once-nightly GHB dosing and “in bed” instructions.
• Design-around routes include:
  • altering selection thresholds (e.g., not using ≤15),
  • changing dose equivalence ranges,
  • removing “while in bed / lie down immediately” instruction from practice (and challenging whether practice causes infringement),
  • using different release architecture that does not have the claimed “immediate-release portion and modified-release portion” structure.

---

What is the likely overlap with Orange Book and FDA labeling triggers?

Featured snippet answer: If the patented method aligns with labeled precautions or dosing instructions for a once-nightly GHB product, it typically drives stronger enforcement because prescriber conduct and dispensing practice track labeling.

How Orange Book listing typically interacts with method claims

Even without a full Orange Book pull in this analysis, the mechanism is standard:

• Drug products with listed patents create a framework where generic applicants must address those patents.
• For method patents tied to prescribing and administration instructions, the litigation focus often becomes whether:
  • a generic’s label encourages prescribing that meets the claim elements, and
  • the generic product has a formulation and dosing profile that reads on the “IR + modified-release” and dose-equivalence constraints.

---

What generic entry risks exist for products that target the same patient cohort?

Featured snippet answer: Generic or follow-on GHB products that provide a once-nightly IR + modified-release regimen with dosing equivalent to sodium oxybate grams may face risk if prescribers follow AHI-based selection workflows (AHI ≤ 15) and in-bed dosing instructions.

High-risk infringement scenarios

• Prescriber workflow includes AHI determination and treats only patients with AHI ≤ 15.
• The generic’s label and REMS-like instructions align with “take once per night while in bed” behavior.
• Clinical studies or prescribing protocols demonstrate the dosing is equivalent to sodium oxybate ranges.

Lower-risk scenarios

• Prescribing guidelines do not use the same AHI threshold or do not link prescribing to AHI determination.
• The product uses a different release architecture that avoids the literal “immediate-release portion” plus “modified-release portion” requirement.
• Dosing practice does not include “while in bed” immediate lying down instructions as a required step.

---

How strong is this patent estate, based on claim structure rather than external citations?

Featured snippet answer: Strength comes from claim specificity and multiple independent procedural and product constraints, which increases the number of elements an accused method must satisfy.

Strength factors

• Bright-line clinical threshold (AHI ≤ 15) plus a comparative exclusion framework (Claim 6).
• Specific administration workflow (prescribe after determining AHI; take while in bed; lie down immediately).
• Specific formulation architecture (IR + modified-release) plus dosing equivalence ranges tied to sodium oxybate.

Vulnerability factors

• Equivalence disputes around “amount of GHB equivalent to sodium oxybate grams.”
• Construction disputes around what constitutes “immediate-release portion” and “modified-release portion.”
• Safety dependent outcomes in Claims 2–4 could be attacked as difficult to prove or as not limiting depending on claim construction.

---

Key Takeaways

• US Patent 11,779,557 claims a once-nightly GHB regimen with IR + modified-release split and dose equivalence to 3–9 g sodium oxybate, plus a prescribing workflow that requires AHI ≤ 15 before treatment.
• Dependent claims add respiratory-safety endpoints: no clinically significant worsening by AHI and pulse oximetry, fewer central apneas vs immediate-release sodium oxybate, and no oxygen desaturation ≤55%.
• Claim 6 adds an explicit treatment inclusion/exclusion structure using AHI ≤ 15 vs AHI > 15 and a narrower lower dose bound (4.5–9 g equivalent).
• The strongest infringement theories typically combine (i) AHI-based selection behavior and (ii) formulation architecture plus (iii) in-bed immediate lying-down administration instructions.

---

FAQs

1. What patient selection step triggers infringement under US 11,779,557?

A “determining” step establishing AHI ≤ 15 before prescribing is a core element of Claim 1, with Claim 6 requiring inclusion/exclusion based on AHI ≤ 15 vs AHI > 15.

2. Does US 11,779,557 require proof of improved respiratory outcomes in the independent claims?

No. Dependent claims add respiratory outcomes, but Claim 1’s core requirements are AHI threshold selection, formulation structure, dosing equivalence range, and in-bed administration timing behavior.

3. Can a product avoid infringement by changing the GHB dose outside 3–9 g sodium oxybate equivalents?

Shifting dosing below 3 g equivalent (or above 9 g equivalent) can avoid Claim 1’s range; shifting below 4.5 g equivalent may avoid Claim 6’s lower bound, assuming other elements still read.

4. What is the role of polysomnography (PSG) in US 11,779,557?

Claim 5 adds a further limitation of PSG measurement; Claim 1 and Claim 6 require AHI determination but Claim 5 specifically ties the process to PSG.

5. How does the “while in bed” instruction affect method claim risk?

It creates an operational step that can align with label-like administration practices; avoiding that behavior in actual practice can reduce the chance all elements are satisfied for method infringement.

---

References

1. United States Patent No. 11,779,557.

Drugs Protected by US Patent 11,779,557

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-001	May 1, 2023		RX	Yes	Yes	11,779,557					TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY WHO HAVE AN APNEA/HYPOPNEA INDEX ≤15 WITH A ONCE-NIGHTLY FORMULATION OF GAMMA-HYDROXYBUTYRATE
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-002	May 1, 2023		RX	Yes	No	11,779,557					TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY WHO HAVE AN APNEA/HYPOPNEA INDEX ≤15 WITH A ONCE-NIGHTLY FORMULATION OF GAMMA-HYDROXYBUTYRATE
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-003	May 1, 2023		RX	Yes	No	11,779,557					TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY WHO HAVE AN APNEA/HYPOPNEA INDEX ≤15 WITH A ONCE-NIGHTLY FORMULATION OF GAMMA-HYDROXYBUTYRATE
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-004	May 1, 2023		RX	Yes	No	11,779,557					TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY WHO HAVE AN APNEA/HYPOPNEA INDEX ≤15 WITH A ONCE-NIGHTLY FORMULATION OF GAMMA-HYDROXYBUTYRATE